Item 1. Financial Statements
ITEM 1. FINANCIAL STATEMENTS
OSI SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(amounts in thousands, except share amounts and par value)
June 30,
March 31,
2025
2026
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
$
106,405
$
345,236
Accounts receivable, net
837,743
870,450
Inventories
407,174
435,290
Prepaid expenses and other current assets
71,539
66,357
Total current assets
1,422,861
1,717,333
Property and equipment, net
126,747
125,765
Goodwill
387,393
385,075
Intangible assets, net
183,290
183,317
Other assets
120,966
142,941
Total assets
$
2,241,257
$
2,554,431
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES:
Bank lines of credit
$
178,000
$
—
Current portion of long-term debt
8,130
3,791
Accounts payable
205,181
200,882
Accrued payroll and related expenses
49,535
51,003
Advances from customers
68,184
59,998
Deferred revenue
77,788
89,358
Other accrued expenses and current liabilities
110,120
124,139
Total current liabilities
696,938
529,171
Long-term debt, net
463,504
998,748
Deferred income taxes
3,334
1,442
Other long-term liabilities
126,397
130,755
Total liabilities
1,290,173
1,660,116
Commitments and contingencies (Note 10)
STOCKHOLDERS’ EQUITY:
Preferred stock, $ 0.001 par value— 10,000,000 shares authorized; no shares issued or outstanding
—
—
Common stock, $ 0.001 par value— 100,000,000 shares authorized; issued and outstanding, 16,794,399 shares at June 30, 2025 and 16,482,544 shares at March 31, 2026
29,758
13,028
Retained earnings
942,254
902,187
Accumulated other comprehensive loss
( 20,928 )
( 20,900 )
Total stockholders’ equity
951,084
894,315
Total liabilities and stockholders’ equity
$
2,241,257
$
2,554,431
See accompanying notes to condensed consolidated financial statements.
3
Table of Contents
OSI SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(amounts in thousands, except per share data)
Three Months Ended March 31,
Nine Months Ended March 31,
2025
2026
2025
2026
Net revenues:
Products
$
341,179
$
344,921
$
930,658
$
971,493
Services
103,175
108,325
277,523
330,433
Total net revenues
444,354
453,246
1,208,181
1,301,926
Cost of goods sold:
Products
236,667
242,574
631,176
693,641
Services
57,396
60,348
158,061
183,147
Total cost of goods sold
294,063
302,922
789,237
876,788
Gross profit
150,291
150,324
418,944
425,138
Operating expenses:
Selling, general and administrative
73,249
71,487
216,194
208,643
Research and development
18,570
19,455
54,600
59,641
Impairment, restructuring and other charges
2,255
6,168
3,648
11,772
Total operating expenses
94,074
97,110
274,442
280,056
Income from operations
56,217
53,214
144,502
145,082
Interest and other expense, net
( 8,228 )
( 3,995 )
( 24,206 )
( 22,106 )
Income before income taxes
47,989
49,219
120,296
122,976
Provision for income taxes
( 6,855 )
( 9,003 )
( 23,407 )
( 23,505 )
Net income
$
41,134
$
40,216
$
96,889
$
99,471
Earnings per share:
Basic
$
2.45
$
2.44
$
5.78
$
5.95
Diluted
$
2.40
$
2.33
$
5.67
$
5.71
Shares used in per share calculation:
Basic
16,781
16,474
16,749
16,706
Diluted
17,159
17,291
17,089
17,414
See accompanying notes to condensed consolidated financial statements.
4
Table of Contents
OSI SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED )
(amounts in thousands)
Three Months Ended March 31,
Nine Months Ended March 31,
2025
2026
2025
2026
Net income
$
41,134
$
40,216
$
96,889
$
99,471
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax
2,386
( 2,269 )
( 5,895 )
( 47 )
Net unrealized gain (loss) on derivatives, net of tax
( 917 )
574
( 2,455 )
120
Other, net of tax
—
( 217 )
380
( 45 )
Other comprehensive income (loss)
1,469
( 1,912 )
( 7,970 )
28
Comprehensive income
$
42,603
$
38,304
$
88,919
$
99,499
See accompanying notes to condensed consolidated financial statements.
5
Table of Contents
OSI SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)
(amounts in thousands, except share data)
Three Months Ended March 31, 2025
Accumulated
Common Stock
Other
Number of
Retained
Comprehensive
Shares
Amount
Earnings
Loss
Total
Balance—December 31, 2024
16,745,805
$
8,933
$
848,372
$
( 31,475 )
$
825,830
Exercise of stock options
9,019
798
—
—
798
Vesting of RSUs
503
—
—
—
—
Shares issued under employee stock purchase plan
33,478
2,582
—
—
2,582
Stock-based compensation expense
—
7,563
—
—
7,563
Taxes paid related to net share settlement of equity awards
( 188 )
( 51 )
—
—
( 51 )
Net income
—
—
41,134
—
41,134
Other comprehensive income
—
—
—
1,469
1,469
Balance—March 31, 2025
16,788,617
$
19,825
$
889,506
$
( 30,006 )
$
879,325
Three Months Ended March 31, 2026
Accumulated
Common Stock
Other
Number of
Retained
Comprehensive
Shares
Amount
Earnings
Loss
Total
Balance—December 31, 2025
16,451,756
$
2,507
$
861,971
$
( 18,988 )
$
845,490
Exercise of stock options
9,687
1,099
—
—
1,099
Vesting of RSUs
858
—
—
—
—
Shares issued under employee stock purchase plan
20,574
2,931
—
—
2,931
Stock-based compensation expense
—
6,585
—
—
6,585
Taxes paid related to net share settlement of equity awards
( 331 )
( 94 )
—
—
( 94 )
Net income
—
—
40,216
—
40,216
Other comprehensive loss
—
—
—
( 1,912 )
( 1,912 )
Balance—March 31, 2026
16,482,544
$
13,028
$
902,187
$
( 20,900 )
$
894,315
6
Table of Contents
OSI SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)
(amounts in thousands, except share data)
Nine Months Ended March 31, 2025
Accumulated
Common Stock
Other
Number of
Retained
Comprehensive
Shares
Amount
Earnings
Loss
Total
Balance—June 30, 2024
17,055,497
$
24,289
$
861,230
$
( 22,036 )
$
863,483
Exercise of stock options
28,229
2,600
—
—
2,600
Vesting of RSUs
322,909
—
—
—
—
Shares issued under employee stock purchase plan
64,621
4,911
—
—
4,911
Stock-based compensation expense
—
22,494
—
—
22,494
Repurchase of common stock
( 531,314 )
( 28,919 )
( 51,524 )
—
( 80,443 )
Taxes paid related to net share settlement of equity awards
( 151,325 )
( 5,550 )
( 17,089 )
—
( 22,639 )
Net income
—
—
96,889
—
96,889
Other comprehensive loss
—
—
—
( 7,970 )
( 7,970 )
Balance—March 31, 2025
16,788,617
$
19,825
$
889,506
$
( 30,006 )
$
879,325
Nine Months Ended March 31, 2026
Accumulated
Common Stock
Other
Number of
Retained
Comprehensive
Shares
Amount
Earnings
Loss
Total
Balance—June 30, 2025
16,794,399
$
29,758
$
942,254
$
( 20,928 )
$
951,084
Exercise of stock options
15,612
1,708
—
—
1,708
Vesting of RSUs
338,715
—
—
—
—
Shares issued under employee stock purchase plan
40,793
5,565
—
—
5,565
Stock-based compensation expense
—
19,835
—
—
19,835
Repurchase of common stock
( 546,945 )
( 7,492 )
( 139,538 )
—
( 147,030 )
Taxes paid related to net share settlement of equity awards
( 160,030 )
( 36,346 )
—
—
( 36,346 )
Net income
—
—
99,471
—
99,471
Other comprehensive income
—
—
—
28
28
Balance—March 31, 2026
16,482,544
$
13,028
$
902,187
$
( 20,900 )
$
894,315
7
Table of Contents
OSI SYSTEMS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
(amounts in thousands)
Nine Months Ended March 31,
2025
2026
CASH FLOWS FROM OPERATING ACTIVITIES
Net income
$
96,889
$
99,471
Adjustments to reconcile net income to net cash provided by operating activities, net of effects from acquisitions:
Depreciation and amortization
32,664
29,388
Stock-based compensation expense
22,494
19,835
Provision for (recovery of) losses on accounts receivable
( 1,677 )
3,335
Deferred income taxes
13
113
Amortization of debt discount and issuance costs
1,249
2,184
Other
134
968
Changes in operating assets and liabilities—net of business acquisitions:
Accounts receivable
( 28,086 )
( 22,396 )
Inventories
( 41,531 )
( 29,589 )
Prepaid expenses and other assets
( 80 )
( 5,171 )
Accounts payable
( 23,133 )
( 3,908 )
Accrued payroll and related expenses
( 2,974 )
4,196
Advances from customers
9,829
( 8,207 )
Deferred revenue
25,780
10,196
Other
5,459
( 6,621 )
Net cash provided by operating activities
97,030
93,794
CASH FLOWS FROM INVESTING ACTIVITIES
Acquisition of property and equipment
( 17,713 )
( 21,272 )
Proceeds from sale of property and equipment
174
6,602
Proceeds from maturities of certificates of deposit
110
—
Acquisition of business, net of cash acquired
( 75,500 )
( 92 )
Payments for intangible and other assets
( 13,517 )
( 13,703 )
Net cash used in investing activities
( 106,446 )
( 28,465 )
CASH FLOWS FROM FINANCING ACTIVITIES
Net repayments on bank lines of credit
( 228,000 )
( 178,000 )
Proceeds from long-term debt
340,575
663,039
Payments on long-term debt
( 6,173 )
( 134,316 )
Proceeds from exercise of stock options and employee stock purchase plan
7,511
7,273
Payment of contingent consideration
( 477 )
( 486 )
Repurchase of common stock
( 80,443 )
( 147,030 )
Taxes paid related to net share settlement of equity awards
( 22,639 )
( 36,346 )
Net cash provided by financing activities
10,354
174,134
Effect of exchange rate changes on cash
( 461 )
( 632 )
Net increase in cash and cash equivalents
477
238,831
Cash and cash equivalents—beginning of period
95,353
106,405
Cash and cash equivalents—end of period
$
95,830
$
345,236
Supplemental disclosure of cash flow information:
Cash paid, net during the period for:
Interest
$
21,869
$
18,495
Income taxes
$
33,464
$
41,328
See accompanying notes to condensed consolidated financial statements.
8
Table of Contents
OSI SYSTEMS, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
1. Basis of Presentation
The unaudited condensed consolidated financial statements include the accounts of OSI Systems, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements have been prepared by management in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and in conjunction with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures required for annual financial statements have been condensed or excluded in accordance with SEC rules and regulations and GAAP applicable to interim unaudited financial statements. Accordingly, the condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for audited annual financial statements. In the opinion of management, the condensed consolidated financial statements reflect all adjustments of a normal and recurring nature that are considered necessary for a fair presentation of the results for the interim periods presented. These unaudited condensed consolidated financial statements and the accompanying notes should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025 filed with the SEC. The results of operations for the three and nine months ended March 31, 2026 are not necessarily indicative of the operating results to be expected for the full 2026 fiscal year or any future periods.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales, costs of sales and expenses during the reporting period. The most significant of these estimates and assumptions for our company relate to contract revenue, fair values of assets acquired and liabilities assumed in business combinations, values for inventories reported at lower of cost or net realizable value, stock-based compensation expense, income taxes, accrued warranty costs, contingent consideration, allowance for doubtful accounts, and the recoverability, useful lives and valuation of recorded amounts of long-lived assets, identifiable intangible assets and goodwill. Changes in estimates are reflected in the periods during which they become known. Due to the inherent uncertainty involved in making estimates, our actual amounts reported in future periods could differ materially from estimated amounts.
Earnings Per Share Computations
We compute basic earnings per share by dividing net income available to common stockholders by the weighted average number of common shares outstanding during the period. We compute diluted earnings per share by dividing net income available to common stockholders by the sum of the weighted average number of common shares and dilutive potential common shares outstanding during the period. Potential common shares consist of the shares issuable upon the exercise of stock options and restricted stock unit awards under the treasury stock method. The underlying equity component of the 2.25 % convertible senior notes due 2029 (the “2029 Notes”) and the 0.50 % convertible senior notes due 2031 (the “2031 Notes”) discussed in Note 8 to the condensed consolidated financial statements will have a net impact on diluted earnings per share when the average price of our common stock exceeds the conversion price of $ 191.98 for the 2029 Notes and $ 353.82 for the 2031 Notes because the principal amounts of the respective convertible senior notes will be settled in cash upon conversion. There was a dilutive effect of the 2029 Notes as set forth in the table below for the three and nine months ended March 31, 2026. There was no dilutive impact of the 2031 Notes.
9
Table of Contents
The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share amounts):
Three Months Ended March 31,
Nine Months Ended March 31,
2025
2026
2025
2026
Net income available to common stockholders
$
41,134
$
40,216
$
96,889
$
99,471
Weighted average shares outstanding—basic
16,781
16,474
16,749
16,706
Dilutive effect of equity awards
378
260
340
265
Dilutive effect of 2029 Notes
—
557
—
443
Weighted average shares outstanding—diluted
17,159
17,291
17,089
17,414
Basic earnings per share
$
2.45
$
2.44
$
5.78
$
5.95
Diluted earnings per share
$
2.40
$
2.33
$
5.67
$
5.71
Shares excluded from diluted earnings per share due to their anti-dilutive effect
16
8
10
9
Cash and Cash Equivalents
We consider all highly liquid investments with maturities of three months or less as of the acquisition date to be cash equivalents.
Our cash and cash equivalents totaled $ 345.2 million at March 31, 2026. Of this amount, approximately 25 % was held by our foreign subsidiaries and subject to repatriation tax considerations. These foreign funds were held primarily by our subsidiaries in the United Kingdom, India, Singapore, Canada, and Malaysia and to a lesser extent Albania, Australia, and Guatemala, among other countries. We have cash holdings in financial institutions that exceed insured limits for such financial institutions; however, we mitigate this risk by utilizing international financial institutions which we believe to be of high credit quality.
Fair Value of Financial Instruments
Our financial instruments consist primarily of cash and cash equivalents, insurance company contracts, accounts receivable, accounts payable, debt instruments, an interest rate swap contract, a cross-currency interest rate swap contract and foreign currency forward contracts. The carrying values of financial instruments, other than long-term debt instruments and our interest rate swap contract, are representative of their fair values due to their short-term maturities. The carrying values of our long-term debt instruments are considered to approximate their fair values because the interest rates of these instruments are variable or comparable to current rates for financing available to us. The fair values of our foreign currency forward contracts were not significant as of June 30, 2025 or as of March 31, 2026.
Fair value is the price that would be received in the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The “Level 1” category includes assets and liabilities at quoted prices in active markets for identical assets and liabilities. The “Level 2” category includes assets and liabilities from observable inputs other than quoted market prices. The “Level 3” category includes assets and liabilities for which valuation techniques are unobservable and significant to the fair value measurement. Our contingent payment obligations related to acquisitions, which are further discussed in Note 10 to the condensed consolidated financial statements, are in the “Level 3” category for valuation purposes.
The fair values of our financial assets and liabilities are categorized as follows (in thousands):
June 30, 2025
March 31, 2026
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
Total
Assets—Insurance company contracts
$
—
$
54,437
$
—
$
54,437
$
—
$
59,511
$
—
$
59,511
Assets – Interest rate swap contract
$
—
$
932
$
—
$
932
$
—
$
544
$
—
$
544
Liabilities—Convertible notes
$
—
$
472,770
$
—
$
472,770
$
—
$
1,123,053
$
—
$
1,123,053
Liabilities—Contingent consideration
$
—
$
—
$
19,086
$
19,086
$
—
$
—
$
11,294
$
11,294
10
Table of Contents
Derivative Instruments and Hedging Activity
Our use of derivatives consists of foreign currency forward contracts, a cross-currency interest rate swap contract and an interest rate swap agreement. Our foreign currency forward contracts are utilized to partially mitigate certain balance sheet exposures or used as a net investment hedge to protect against potential changes resulting from short-term foreign currency fluctuations. These foreign currency forward contracts have original maturities of up to three months. We use a cross-currency interest rate swap contract to hedge our net investment in a foreign subsidiary. We also manage our risk to changes in interest rates using derivative instruments. We use fixed interest rate swaps to effectively convert a portion of the variable interest rate payments to fixed interest rate payments. We do not use hedging instruments for speculative purposes.
The net gains or losses from our foreign currency forward contracts, which are not designated as hedge instruments, are reported in the consolidated statements of operations, and the amounts reported for the three and nine months ended March 31, 2025 and 2026 were not significant. The fair value of our foreign currency forward contracts is estimated using a standard valuation model and market-based observable inputs over the contractual term. Unrealized gains are recognized as assets and unrealized losses are recognized as liabilities. As of June 30, 2025 and March 31, 2026, we held foreign currency forward contracts with notional amounts totaling $ 99.9 million and $ 145.7 million, respectively. Unrealized gains and losses from our foreign currency forward contracts as of June 30, 2025 and March 31, 2026 were not significant.
We entered into a cross-currency interest rate swap contract in March 2026, which matures in June 2026. The net gains or losses from our cross-currency interest rate swap contract, which is designated as a net investment hedge instrument in a foreign subsidiary, are reported in accumulated other comprehensive loss in the consolidated statements of stockholders’ equity, and the amounts reported for the three and nine months ended March 31, 2026 were not significant. The fair value of our cross-currency interest rate swap contract is estimated using a standard valuation model and market-based observable inputs over the contractual term. Unrealized gains are recognized as assets and unrealized losses are recognized as liabilities. As of March 31, 2026, the notional amount of this contract was $ 35.0 million. The unrealized gain from our cross-currency interest rate swap contract as of March 31, 2026 was not significant. The net interest rate benefit from this contract recognized in interest and other expense, net was not significant for the three and nine months ended March 31, 2026.
Our interest rate swap agreement was entered into to improve the predictability of cash flows from interest payments related to our variable, Secured Overnight Financing Rate (“SOFR”)-based debt. The interest rate swap matures in December 2026. The interest rate swap is considered an effective cash flow hedge, and as a result, the net gains or losses on such instrument are reported as a component of other comprehensive income (loss) in our consolidated financial statements and are reclassified as net income when the underlying hedged interest impacts earnings. A qualitative and quantitative assessment of the interest rate swap hedge effectiveness is performed on a quarterly basis, unless facts and circumstances indicate that the hedge may no longer be highly effective. As of June 30, 2025 and March 31, 2026, the notional amount of the derivative instrument designated as an interest rate swap hedge was $ 175.0 million. The fair value of the interest rate swap agreement as of June 30, 2025 and March 31, 2026 is recorded in Other assets within the consolidated balance sheet.
The effect of the interest rate swap cash flow hedge on other comprehensive income (loss) and earnings for the periods presented was as follows:
Three Months Ended March 31,
Nine Months Ended March 31,
2025
2026
2025
2026
Total interest and other expense, net presented in the condensed consolidated statements of operations in which the effects of cash flow hedge are recorded
$
( 8,228 )
$
( 3,995 )
$
( 24,206 )
$
( 22,106 )
Gain (loss) recognized in other comprehensive income (loss), net of tax
$
( 917 )
$
220
$
( 2,455 )
$
( 234 )
Benefit reclassified from accumulated other comprehensive income (loss) to interest expense, net
$
449
$
170
$
1,984
$
956
Recent Accounting Pronouncements
From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) and other regulatory bodies that are adopted as of the specified effective dates. Unless otherwise discussed, management believes that the impact of recently issued standards, which are not yet effective, will not have a material impact on our Consolidated Financial Statements upon adoption. There were no new pronouncements adopted in the third quarter of fiscal year 2026.
11
Table of Contents
Accounting Guidance Not Yet Adopted
In December 2023, the FASB issued Accounting Standards Update 2023-09, “Improvements to Income Tax Disclosures” (“ASU 2023-09”), which provides for additional disclosures primarily related to income tax rate reconciliations and income taxes paid. ASU 2023-09 requires entities to annually disclose income tax rate reconciliation using both amounts and percentages, considering several categories of reconciling items, including state and local income taxes, foreign tax effects, tax credits and nontaxable or nondeductible items, among others. Disclosure of reconciling items is subject to a quantitative threshold and disaggregation by nature and jurisdiction. ASU 2023-09 also requires entities to disclose net income taxes paid to or received from federal, state and foreign jurisdictions, as well as by individual jurisdiction, subject to a five percent quantitative threshold. ASU 2023-09 may be adopted on a prospective or retrospective basis. We are evaluating the potential impact of ASU 2023-09 on disclosures in our Consolidated Financial Statements which is effective beginning with our Form 10-K for the current fiscal year 2026.
In November 2024, the FASB issued Accounting Standards Update 2024-03, “ Income Statement-Reporting Comprehensive Income (Topic 220): Expense Disaggregation Disclosures”, (“ASU 2024-03”) which requires additional disclosures about income statement expenses. The guidance requires disaggregation of certain costs and expenses included in each relevant expense caption on our consolidated income statements in a separate note to the financial statements at each interim and annual reporting period, including amounts of purchases of inventory, employee compensation, depreciation, and intangible asset amortization. ASU 2024-03 is effective for annual periods beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted and may be applied either on a prospective or retrospective basis. We are evaluating the potential impact of ASU 2024-03 on disclosures in our Consolidated Financial Statements which will be effective beginning with our Form 10-K for fiscal year 2028.
In September 2025, the FASB issued Accounting Standards Update 2025-06 “Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software” (“ASU 2025-06”) which modernizes the accounting for internal-use software to current development practices, clarifies when to begin capitalizing costs and enhances disclosure requirements. This standard is effective for annual reporting periods beginning after December 15, 2027, including interim periods within those annual periods. Early adoption is permitted. The amendments are to be applied retrospectively, prospectively, or a modified transition approach may be used based on the status of the project and whether software costs were capitalized before the date of adoption. We are evaluating the potential impact of ASU 2025-06 on disclosures in our Consolidated Financial Statements which will be effective beginning with our Form 10-K for fiscal year 2029.
In December 2025, the FASB issued ASU 2025-11, “Interim Reporting (Topic 270): Narrow-Scope Improvements” (ASU 2025-11”), which clarifies the application, form and content, and required disclosures for interim financial statements prepared in accordance with GAAP. The ASU improves the organization and clarity of ASU 2025-11 by specifying interim reporting requirements, consolidating required interim disclosures and introducing a disclosure principle for events and changes occurring after the end of the most recent annual reporting period that have a material impact on the entity. ASU 2025-11 is effective for interim periods within annual reporting periods beginning after December 15, 2027, with early adoption permitted. We are evaluating the potential impact of ASU 2025-11 on disclosures in our Consolidated Financial Statements which will be effective for interim periods beginning fiscal year 2029.
In December 2025, the FASB issued Accounting Standards Update 2025-12, “Codification Improvements” (“ASU 2025-12”). ASU 2025-12 includes changes that clarify, correct, or otherwise improve certain components of the Accounting Standards Codification. The improvements consist of narrow-scope amendments, technical corrections, clarification of existing guidance, and updates to clarify the appropriate scope and application of certain disclosure requirements. ASU 2025-12 is effective for annual periods beginning after December 15, 2026. We are evaluating the potential impact of ASU 2025-12 on disclosures in our Consolidated Financial Statements which will be effective beginning with our Form 10-K for fiscal year 2028.
12
Table of Contents
2. Business Combinations
Under Accounting Standards Codification Topic 805, Business Combinations (“ASC 805”), the acquisition method of accounting requires us to record assets acquired less liabilities assumed from an acquisition at their estimated fair values at the date of acquisition. Any excess of the total estimated purchase price over the estimated fair value of the net assets acquired should be recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired customers, acquired technology, trade names, useful lives and discount rates. Management’s estimates of fair value are based on assumptions which are believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period for fair value, which is up to one year from the acquisition date, as additional information that existed at the acquisition date becomes available, we may record adjustments to the preliminary assets acquired and liabilities assumed. Upon the conclusion of the measurement period, any subsequent adjustments are included in earnings.
Fiscal Year 2025 Business Acquisitions
In September 2024, we (through our Security division) acquired 100 % of the shares of common stock of a privately held provider of critical military, space and surveillance solutions to expand our customer base and offer additional products and services for existing customers, for approximately $ 76.0 million, plus up to $ 24.0 million in potential contingent consideration. We paid $ 75.5 million in cash at the closing of the transaction. The cash paid for this acquisition was financed with borrowings from our credit facility. The acquisition date fair value of the contingent consideration was $ 9.7 million, which, when combined with the amount of cash paid at close and the holdback amount, resulted in total purchase consideration of $ 85.7 million being allocated to the preliminary fair value of assets acquired and liabilities assumed. The acquisition date fair value of total assets acquired, including measurement period adjustments, was $ 113.9 million which comprised accounts receivable of $ 26.1 million, inventory and other current assets of $ 2.7 million, property and equipment of $ 7.0 million, goodwill of $ 30.7 million, other intangible assets of $ 47.3 million and other noncurrent assets of $ 0.1 million. Goodwill includes the value of the assembled workforce, new customers and other future economic benefits which do not qualify for separate recognition. The goodwill recognized for this business acquisition is not deductible for income tax purposes. Other intangible assets include amortizable intangible assets of $ 36.7 million with amortization periods of 7 to 10 years and an indefinite-lived intangible asset of $ 8.1 million. The acquisition date fair value of total liabilities assumed, including measurement period adjustments, was $ 28.2 million, which includes a deferred tax liability of $ 7.3 million that was recognized primarily due to the acquisition of other intangible assets. During the three months ended September 30, 2025, we recorded measurement period adjustments which decreased goodwill by $ 1.4 million due to a decrease in deferred income taxes of $ 1.8 million and an increase in intangible assets of $ 0.1 million, which were partially offset by a decrease in accounts receivable of $ 0.5 million. The measurement period adjustments did not have a significant impact on the consolidated statement of operations. The measurement period ended in September 2025, and no further purchase price adjustments have been recorded since.
In April 2025, we (through our Security division) acquired a privately held provider of engineering and structural component services for approximately $ 1.3 million, plus up to $ 0.9 million in potential contingent consideration. The acquisition was financed with cash on hand. The goodwill recognized for this business acquisition is not deductible for income tax purposes.
3. Balance Sheet Details
The following tables set forth details of selected balance sheet accounts (in thousands):
June 30,
March 31,
Accounts receivable, net
2025
2026
Accounts receivable
$
855,494
$
890,357
Less allowance for doubtful accounts
( 17,751 )
( 19,907 )
Total
$
837,743
$
870,450
13
Table of Contents
June 30,
March 31,
Inventories
2025
2026
Raw materials
$
245,993
$
260,741
Work-in-process
72,124
107,322
Finished goods
89,057
67,227
Total
$
407,174
$
435,290
June 30,
March 31,
Property and equipment, net
2025
2026
Land
$
16,087
$
15,477
Buildings, civil works and improvements
55,559
51,824
Leasehold improvements
14,636
14,911
Equipment, tooling, furniture and fixtures
158,411
158,818
Computer equipment
24,092
27,107
Computer software
30,954
31,878
Computer software implementation in process
4,472
4,632
Construction in process
7,370
12,845
Total
311,581
317,492
Less accumulated depreciation and amortization
( 184,834 )
( 191,727 )
Property and equipment, net
$
126,747
$
125,765
Depreciation and amortization expense for property and equipment was $ 5.0 million and $ 5.1 million for the three months ended March 31, 2025 and 2026, respectively, and $ 16.7 million and $ 15.7 million for the nine months ended March 31, 2025 and 2026, respectively.
4. Goodwill and Intangible Assets
The changes in the carrying value of goodwill by segment for the nine-month period ended March 31, 2026 were as follows (in thousands):
Optoelectronics
And
Security
Manufacturing
Healthcare
Division
Division
Division
Consolidated
Balance as of June 30, 2025
$
266,365
$
72,323
$
48,705
$
387,393
Goodwill adjustments during the period (see Note 2)
( 1,306 )
—
—
( 1,306 )
Foreign currency translation adjustment
13
( 911 )
( 114 )
( 1,012 )
Balance as of March 31, 2026
$
265,072
$
71,412
$
48,591
$
385,075
Intangible assets consisted of the following (in thousands):
June 30, 2025
March 31, 2026
Gross
Gross
Carrying
Accumulated
Intangibles
Carrying
Accumulated
Intangibles
Value
Amortization
Net
Value
Amortization
Net
Amortizable assets:
Software development costs
$
91,386
$
( 8,941 )
$
82,445
$
104,067
$
( 10,755 )
$
93,312
Patents
9,617
( 4,353 )
5,264
9,809
( 4,559 )
5,250
Developed technology
99,937
( 55,865 )
44,072
98,747
( 62,801 )
35,946
Customer relationships
20,991
( 9,380 )
11,611
18,364
( 9,551 )
8,813
Total amortizable assets
221,931
( 78,539 )
143,392
230,987
( 87,666 )
143,321
Non-amortizable assets:
Trademarks
39,898
—
39,898
39,996
—
39,996
Total intangible assets
$
261,829
$
( 78,539 )
$
183,290
$
270,983
$
( 87,666 )
$
183,317
14
Table of Contents
Amortization expense related to intangible assets was $ 5.6 million and $ 4.4 million for the three months ended March 31, 2025 and 2026, respectively. Amortization expense related to intangible assets was $ 15.9 million and $ 13.6 million for the nine months ended March 31, 2025 and 2026, respectively.
At March 31, 2026, the estimated future amortization expense for amortizable intangible assets was as follows (in thousands):
Fiscal Year
2026 (remaining 3 months)
$
4,459
2027
13,814
2028
10,241
2029
8,057
2030
7,395
Thereafter
99,355
Total
$
143,321
Software development costs for software products incurred before establishing technological feasibility are charged to operations. Software development costs incurred after establishing technological feasibility are capitalized on a product-by-product basis until the product is available for general release to customers at which time amortization begins. Annual amortization, charged to cost of goods sold, is the amount computed using the ratio that current revenues for a product bear to the total current and anticipated future revenues for that product. In the event that future revenues are not estimable, such costs are amortized on a straight-line basis over the remaining estimated economic life of the product. Amortizable assets that have not yet begun to be amortized are included in Thereafter in the table above. For each of the three months ended March 31, 2025 and 2026, we capitalized software development costs of $ 4.2 million. For the nine months ended March 31, 2025 and 2026, we capitalized software development costs in the amounts of $ 13.0 million and $ 13.1 million, respectively.
5. Contract Assets and Liabilities
We enter into contracts to sell products and provide services, and we recognize contract assets and liabilities that arise from these transactions. We recognize revenue and corresponding accounts receivable according to ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). When we recognize revenue in advance of the point in time at which contracts give us the right to invoice a customer, we record this as unbilled revenue, which is included in accounts receivable, net, on the consolidated balance sheets. We may also receive consideration, per the terms of a contract, from customers prior to transferring control of goods to the customer. We record customer deposits as contract liabilities. Additionally, we may receive payments, most typically under service and warranty contracts, at the onset of the contract and before services have been performed. In such instances, we record a deferred revenue liability in either Other accrued expenses and current liabilities or Other long-term liabilities. We recognize these contract liabilities as sales after all revenue recognition criteria are met.
The table below shows the balance of contract assets and liabilities as of June 30, 2025 and March 31, 2026, including the change between such dates. There were no substantial non-current contract assets for the periods presented.
Contract Assets (in thousands)
June 30,
March 31,
2025
2026
Change
% Change
Unbilled revenue (included in accounts receivable, net)
$
242,742
$
174,839
$
( 67,903 )
( 28.0 )
%
Contract Liabilities (in thousands)
June 30,
March 31,
2025
2026
Change
% Change
Advances from customers
$
68,184
$
59,998
$
( 8,186 )
( 12.0 )
%
Deferred revenue—current
77,788
89,358
11,570
14.9
%
Deferred revenue—long-term
18,856
19,385
529
2.8
%
15
Table of Contents
Contract Assets. Contract assets decreased $ 67.9 million primarily due to achievement of certain contractual milestones in our Security division, giving us the right to invoice customers.
Contract Liabilities . Advances from customers decreased $ 8.2 million primarily due to application of certain amounts to customer invoices during the period. Total deferred revenue increased $ 12.1 million primarily due to service contracts which allow us to collect payment prior to performance of these obligations.
Remaining Performance Obligations . Remaining performance obligations related to ASC 606 represent the portion of the transaction price allocated to performance obligations under an original contract with a term greater than one year which are fully or partially unsatisfied at the end of the period. As of March 31, 2026, the portion of the transaction price allocated to remaining performance obligations was approximately $ 877.2 million. We expect to recognize revenue on approximately 37 % of the remaining performance obligations over the next 12 months , and the remainder is expected to be recognized thereafter. During the nine months ended March 31, 2026, we recognized revenue of $ 81.8 million from contract liabilities existing at the beginning of the period.
Practical Expedients. In cases where we are responsible for shipping after the customer has obtained control of the goods, we have elected to treat the shipping activities as fulfillment activities rather than as separate performance obligations. Additionally, we have elected to capitalize the cost to obtain a contract only if the period of amortization would be longer than one year. We only give consideration to whether a customer agreement has a financing component if the period of time between transfer of goods and services and customer payment is greater than one year.
6. Leases
The components of operating lease expense were as follows (in thousands):
Three Months Ended March 31,
Nine Months Ended March 31,
2025
2026
2025
2026
Operating lease cost
$
3,399
$
3,943
$
9,017
$
11,146
Variable lease cost
256
224
735
758
Short-term lease cost
427
231
1,358
772
$
4,082
$
4,398
$
11,110
$
12,676
Supplemental disclosures related to operating leases were as follows (in thousands):
Balance Sheet Category
June 30, 2025
March 31, 2026
Operating lease right of use (“ROU”) assets, net
Other assets
$
32,040
$
41,698
Operating lease liabilities, current portion
Other accrued expenses and current liabilities
$
11,712
$
13,086
Operating lease liabilities, long-term
Other long-term liabilities
20,977
29,586
Total operating lease liabilities
$
32,689
$
42,672
Weighted average remaining lease term
5.4 years
Weighted average discount rate
5.7
%
Supplemental cash flow information related to operating leases was as follows (in thousands):
Nine Months Ended March 31,
2025
2026
Cash paid for operating lease liabilities
$
9,223
$
10,701
ROU assets obtained in exchange for new lease obligations
5,521
17,680
16
Table of Contents
Maturities of operating lease liabilities at March 31, 2026 were as follows (in thousands):
March 31, 2026
Less than one year
$
14,997
1 – 2 years
10,367
2 – 3 years
5,781
3 – 4 years
4,185
4 – 5 years
2,739
Thereafter
11,765
49,834
Less: imputed interest
( 7,162 )
Total lease liabilities
$
42,672
7. Impairment, Restructuring and Other Charges
We endeavor to align our global capacity and infrastructure with demand by our customers and to effectively integrate acquisitions and thereby improve our operational efficiency.
During the three months ended March 31, 2026, we recognized $ 6.2 million in impairment, restructuring and other charges, which included $ 0.2 million for impairment of assets, $ 1.7 million for employee terminations, $ 2.0 million for acquisition-related costs, $ 1.2 million for non-recurring business unit modifications and $ 1.1 million for a legal settlement, primarily in our Healthcare division. During the nine months ended March 31, 2026, we recognized $ 11.8 million in impairment, restructuring and other charges, which included $ 1.2 million for impairment of assets, $ 2.7 million for employee terminations, $ 2.0 million for acquisition-related costs, $ 2.6 million for non-recurring business unit modifications and $ 1.1 million for a legal settlement in our Healthcare division, and $ 2.2 million of non-recurring charges in our Security division.
During the three months ended March 31, 2025, we recognized $ 2.3 million in restructuring and other charges, which included $ 1.8 million in employee terminations and $ 0.5 million for facility closure costs. During the nine months ended March 31, 2025, we recognized $ 3.6 million in restructuring and other charges, which included $ 0.6 million in acquisition-related costs, $ 0.8 million for facility closure costs for operational efficiency activities, and $ 2.3 million for employee terminations.
The following tables summarize impairment, restructuring and other charges (benefits), net for the periods set forth below (in thousands):
Three Months Ended March 31, 2025
Optoelectronics and
Manufacturing
Healthcare
Security Division
Division
Division
Corporate
Total
Acquisition-related costs (recoveries), net
$
( 29 )
$
—
$
—
$
14
$
( 15 )
Employee termination costs
910
72
627
139
1,748
Facility closures/consolidation
522
—
—
—
522
Total
$
1,403
$
72
$
627
$
153
$
2,255
Three Months Ended March 31, 2026
Optoelectronics and
Manufacturing
Healthcare
Security Division
Division
Division
Corporate
Total
Acquisition-related costs
$
—
$
—
$
—
$
1,950
$
1,950
Employee termination costs
1,243
155
165
149
1,712
Impairment of assets
198
—
—
—
198
Legal and other expense (benefit), net
( 8 )
( 155 )
2,471
—
2,308
Total
$
1,433
$
—
$
2,636
$
2,099
$
6,168
17
Table of Contents
Nine Months Ended March 31, 2025
Optoelectronics and
Manufacturing
Healthcare
Security Division
Division
Division
Corporate
Total
Acquisition-related costs
$
341
$
—
$
—
$
228
$
569
Employee termination costs
1,012
391
779
140
2,322
Facility closures/consolidation
529
242
—
—
771
Legal costs (reimbursements), net
—
( 14 )
—
—
( 14 )
Total
$
1,882
$
619
$
779
$
368
$
3,648
Nine Months Ended March 31, 2026
Optoelectronics and
Manufacturing
Healthcare
Security Division
Division
Division
Corporate
Total
Acquisition-related costs
$
27
$
—
$
—
$
1,950
$
1,977
Employee termination costs
1,742
416
458
149
2,765
Impairment of assets
1,154
—
—
—
1,154
Legal and other expense (benefit), net
2,164
( 155 )
3,867
—
5,876
Total
$
5,087
$
261
$
4,325
$
2,099
$
11,772
The accrued liability for impairment, restructuring and other charges is included in Other accrued expenses and current liabilities in our condensed consolidated balance sheets. The changes in the accrued liability for impairment, restructuring and other charges for the nine-month period ended March 31, 2026 were as follows (in thousands):
Facility
Acquisition-
Employee
Closure/
Legal
Related
Termination
Consolidation
and Other
Costs
Costs
Costs
Costs
Total
Balance as of June 30, 2025
$
—
$
445
$
623
$
1,717
$
2,785
Restructuring and other charges (benefit), net
1,977
2,765
—
5,876
10,618
Payments and adjustments, net
( 27 )
( 2,972 )
( 623 )
( 6,099 )
( 9,721 )
Balance as of March 31, 2026
$
1,950
$
238
$
—
$
1,494
$
3,682
8. Borrowings
Revolving Credit Facility
In July 2025 we amended and extended our credit facility, now maturing in July 2030, to increase the revolving limit from $ 600 million to $ 725 million and replaced the $ 128.1 million term loan with a $ 100.0 million term loan which were accounted for as a debt modification. The sub-limit for letters of credit was increased from $ 300 million to $ 350 million, which includes up to $ 300 million for borrowings in certain foreign currencies. Under certain circumstances and subject to certain conditions, we have the ability to increase the revolving credit facility by an amount equal to the greater of $ 300 million or such amount as would not cause our secured leverage ratio to exceed a specified level. Other enhancements include the permitted securitization of certain qualifying assets of up to $ 100 million.
18
Table of Contents
Borrowings under the facility bore interest at SOFR plus a margin of 1.25 % as of March 31, 2026 (which margin can range from 1.0 % to 1.75 % based on our consolidated net leverage ratio as defined in the credit facility). Letters of credit reduce the amount available to borrow under the credit facility by their face value amount. The unused portion of the facility bore a commitment fee of 0.15 % as of March 31, 2026 (which fee can range from 0.10 % to 0.25 % based on our consolidated net leverage ratio as defined in the credit facility). Our borrowings under the credit agreement are guaranteed by certain of our U.S.-based subsidiaries and are secured by substantially all of our assets and substantially all the assets of certain of our subsidiaries. The credit facility contains various representations and warranties, affirmative, negative and financial covenants and events of default. As of March 31, 2026, there were no borrowings outstanding under the revolving credit facility, $ 106.7 million outstanding under the letters of credit sub-facility, and $ 95.0 million outstanding under the term loan. As of March 31, 2026, the amount available to borrow under the credit facility was $ 618.3 million. Loan amounts under the revolving credit facility may be borrowed, repaid and re-borrowed during the term. The principal amount of each loan is due and payable in full on the maturity date. We have the right to repay each loan in whole or in part from time to time without penalty. It is our practice to routinely borrow and repay several times per year under the revolving facility and therefore, borrowings under the revolving credit facility are included in current liabilities. As of March 31, 2026, we were in compliance with all financial covenants under this credit facility. In September 2022, we entered into an interest rate swap agreement in order to mitigate the interest rate risk on a portion of the interest payments expected to be made on the borrowings outstanding under the revolving credit facility and term loan. Refer to Note 1 for further information relating to the interest rate swap agreement.
2.25 % Convertible Senior Notes Due 2029
In July 2024, we issued an aggregate of $ 350.0 million principal amount of 2.25 % convertible senior notes due in August 2029 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), at an issuance price equal to 97.5 % of the principal amount. The 2029 Notes were issued pursuant to and are governed by an indenture dated July 19, 2024. The proceeds from the issuance of the 2029 Notes were $ 340.4 million, net of the issuance discount and debt issuance costs.
The 2029 Notes are unsecured obligations which bear regular interest at 2.25 % per annum payable semiannually in arrears on February 1 and August 1 of each year. The 2029 Notes will mature on August 1, 2029, unless repurchased, redeemed, or converted in accordance with their terms prior to such date. The 2029 Notes are convertible into a combination of cash and shares of our common stock, at an initial conversion rate of 5.2090 shares of common stock per $1,000 principal amount of 2029 Notes, which is equivalent to an initial conversion price of approximately $ 191.98 per share of our common stock. The default settlement method is a combination settlement with a specified dollar amount of $ 1,000 per $1,000 principal amount of notes. The conversion rate is subject to customary adjustments for certain dilutive events. We may redeem for cash all or any portion of the 2029 Notes, at our option, on or after August 6, 2027 if the last reported sale price of our common stock has been at least 130 % of the conversion price then in effect for at least 20 trading days at a redemption price equal to 100 % of the principal amount of the 2029 Notes to be redeemed, plus accrued and unpaid interest up to the day before the redemption date. The holders of the 2029 Notes may require us to repurchase the 2029 Notes upon the occurrence of certain fundamental change transactions at a redemption price equal to 100 % of the principal amount of the 2029 Notes redeemed, plus accrued and unpaid interest up to the day before the redemption date.
Holders of the 2029 Notes may, at their option, convert all or a portion of their 2029 Notes prior to May 1, 2029, in multiples of $1,000 principal amounts, only (i) during any calendar quarter if our common stock price exceeds 130 % of the conversion price for at least 20 trading days during the 30 consecutive trading days at the end of the prior calendar quarter, (ii) during the five consecutive business days immediately after any 10 consecutive trading day period in which the trading price per $1,000 principal amount of the 2029 Notes for each trading day of the measurement period was less than 98 % of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day, (iii) upon the occurrence of specified corporate events or certain distributions on our common stock; or (iv) if we call any or all of the 2029 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the 2029 Notes called for redemption.
On or after May 1, 2029, the 2029 Notes will be convertible by the holders thereof at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Holders of the 2029 Notes who convert the 2029 Notes in connection with a make-whole fundamental change, as defined in the indenture governing the 2029 Notes, or in connection with a redemption may be entitled to an increase in the conversion rate.
19
Table of Contents
We accounted for the issuance of the 2029 Notes as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives. The following table is a summary of the 2029 Notes as of March 31, 2026 (in thousands):
March 31,
2026
Principal amount
$
350,000
Unamortized debt discount and issuance costs
( 6,408 )
Net carrying amount
$
343,592
Fair value (Level 2)
$
536,375
As of March 31, 2026, one of the conditions allowing holders of the 2029 Notes to convert had been met. The trading price of our common stock remained above 130 % of the applicable $ 191.98 conversion price for at least 20 trading days during the 30 consecutive trading-day period ending on, and including, March 31, 2026 (the last trading day of the quarter ended March 31, 2026), resulting in the right of the holders of the 2029 Notes to convert their 2029 Notes beginning January 2, 2026 through March 31, 2026 (the last trading day of the quarter ending March 31, 2026). Should the holders of the 2029 Notes elect to convert some or all of the 2029 Notes, we intend to draw on our revolving credit facility to settle the obligation. We have sufficient availability on our revolving credit facility to fully refinance the principal amount of the 2029 Notes for more than one year, accordingly, the net carrying amount of the 2029 Notes continues to be classified as a noncurrent liability on the condensed consolidated balance sheets. To the extent that conversion of the 2029 Notes cannot be refinanced with the revolving credit facility in the future, the portion that cannot be refinanced will be classified as current and recorded in current portion of long-term debt on the condensed consolidated balance sheets. No sinking fund is provided for the 2029 Notes, which means that we are not required to redeem or retire them periodically. As of March 31, 2026 we were in compliance with applicable financial covenants under the indenture governing the 2029 Notes.
For each of the three months ended March 31, 2026 and 2025, total interest expense for the 2029 Notes was $ 2.4 million (comprised of $ 2.0 million of contractual interest expense and $ 0.4 million of amortization of debt discount and issuance costs). For the nine months ended March 31, 2026, total interest expense for the 2029 Notes was $ 7.3 million (comprised of $ 5.9 million of contractual interest expense and $ 1.4 million of amortization of debt discount and issuance costs) compared with total interest expense for the 2029 Notes of $ 6.8 million (comprised of $ 5.5 million of contractual interest expense and $ 1.3 million of amortization of debt discount and issuance costs) for the nine months ended March 31, 2025. The unamortized debt issuance cost is amortized on the effective interest method over the life of the 2029 Notes.
0.50 % Convertible Senior Notes Due 2031
In November 2025, we issued an aggregate of $ 575.0 million principal amount of 0.50 % convertible senior notes due in February 2031 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act at an issuance price equal to 98 % of the principal amount. The 2031 Notes were issued pursuant to and are governed by an indenture dated November 20, 2025. The proceeds from the issuance of the 2031 Notes were approximately $ 563.0 million, net of the issuance discount and debt issuance costs.
The 2031 Notes are unsecured obligations which bear regular interest at 0.50 % per annum payable semiannually in arrears on February 1 and August 1 of each year, beginning on August 1, 2026. The 2031 Notes will mature on February 1, 2031, unless repurchased, redeemed, or converted in accordance with their terms prior to such date. The 2031 Notes are convertible into a combination of cash and shares of our common stock, at an initial conversion rate of 2.8263 shares of common stock per $1,000 principal amount of 2031 Notes, which is equivalent to an initial conversion price of approximately $ 353.82 per share of our common stock. The default settlement method is a combination settlement with a specified dollar amount of $ 1,000 per $1,000 principal amount of notes. The conversion rate is subject to customary adjustments for certain dilutive events. We may redeem for cash all or any portion of the 2031 Notes, at our option, on or after February 6, 2029 if the last reported sale price of our common stock has been at least 130 % of the conversion price then in effect for at least 20 trading days at a redemption price equal to 100 % of the principal amount of the 2031 Notes to be redeemed, plus accrued and unpaid interest up to the day before the redemption date. The holders of the 2031 Notes may require us to repurchase the 2031 Notes upon the occurrence of certain fundamental change transactions at a redemption price equal to 100 % of the principal amount of the 2031 Notes redeemed, plus accrued and unpaid interest up to the day before the redemption date.
20
Table of Contents
Holders of the 2031 Notes may, at their option, convert all or a portion of their 2031 Notes prior to November 1, 2030, in multiples of $1,000 principal amounts, only (i) during any calendar quarter if our common stock price exceeds 130 % of the conversion price for at least 20 trading days during the 30 consecutive trading days at the end of the prior calendar quarter, (ii) during the five consecutive business days immediately after any 10 consecutive trading day period in which the trading price per $1,000 principal amount of the 2031 Notes for each trading day of the measurement period was less than 98 % of the product of the last reported sale price per share of our common stock on such trading day and the conversion rate on such trading day, (iii) upon the occurrence of specified corporate events or certain distributions on our common stock; or (iv) if we call any or all of the 2031 Notes for redemption, at any time prior to the close of business on the scheduled trading day immediately preceding the redemption date, but only with respect to the 2031 Notes called for redemption.
On or after November 1, 2030, the 2031 Notes will be convertible by the holders thereof at any time until the close of business on the second scheduled trading day immediately preceding the maturity date. Holders of the 2031 Notes who convert the 2031 Notes in connection with a make-whole fundamental change, as defined in the indenture governing the 2031 Notes, or in connection with a redemption may be entitled to an increase in the conversion rate.
We accounted for the issuance of the 2031 Notes as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition as derivatives. The following table is a summary of the 2031 Notes as of December 31, 2025 (in thousands):
March 31,
2026
Principal amount
$
575,000
Unamortized debt discount and issuance costs
( 11,195 )
Net carrying amount
$
563,805
Fair value (Level 2)
$
586,678
The 2031 Notes were not eligible for conversion as of March 31, 2026. No sinking fund is provided for the 2031 Notes, which means that we are not required to redeem or retire them periodically. As of March 31, 2026 we were in compliance with applicable financial covenants under the indenture governing the 2031 Notes.
For the three months ended March 31, 2026, total interest expense for the 2031 Notes was $ 1.3 million (comprised of $ 0.7 million of contractual interest expense and $ 0.6 million of amortization of debt discount and issuance costs). For the nine months ended March 31, 2026, total interest expense for the 2031 Notes was $ 1.9 million (comprised of $ 1.0 million of contractual interest expense and $ 0.9 million of amortization of debt discount and issuance costs). The unamortized debt issuance cost is amortized on the effective interest method over the life of the 2031 Notes.
Other Borrowings
Several of our foreign subsidiaries maintain bank lines of credit, denominated in local currencies and U.S. dollars, primarily for the issuance of letters of credit. As of March 31, 2026, $ 64.9 million was outstanding under these letter-of-credit facilities. As of March 31, 2026, the total amount available under these credit facilities was $ 55.2 million.
Long-term debt consisted of the following (in thousands):
June 30,
March 31,
2025
2026
Term loan
$
128,125
$
95,000
2029 Notes, net
342,231
343,592
2031 Notes, net
—
563,805
Other long-term debt
1,278
142
471,634
1,002,539
Less current portion of long-term debt
( 8,130 )
( 3,791 )
Long-term portion of debt
$
463,504
$
998,748
21
Table of Contents
Future principal payments of long-term debt by fiscal year as of March 31, 2026 are as follows (in thousands):
2026 (3 months remaining)
$
44
2027
5,060
2028
5,022
2029
5,014
2030 and thereafter
987,399
Total
$
1,002,539
9. Stockholders’ Equity
Stock-based Compensation
As of March 31, 2026, we maintained the Amended and Restated 2012 Incentive Award Plan (the “OSI Plan”) as a stock-based employee compensation plan.
We recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):
Three Months Ended March 31,
Nine Months Ended March 31,
2025
2026
2025
2026
Cost of goods sold
$
258
$
298
$
728
$
874
Selling, general and administrative
7,132
6,119
21,298
18,468
Research and development
173
168
468
493
Stock-based compensation expense
$
7,563
$
6,585
$
22,494
$
19,835
As of March 31, 2026, total unrecognized compensation cost related to share-based compensation grants under the OSI Plan were estimated at $ 1.1 million for stock options and $ 16.4 million for restricted stock units (“RSUs”). We expect to recognize these costs over a weighted average period of 2.0 years with respect to the stock options and 2.2 years with respect to the RSUs.
The following summarizes stock option activity during the nine months ended March 31, 2026:
Weighted
Average
Weighted-Average
Aggregate
Number of
Exercise
Remaining Contractual
Intrinsic Value
Options
Price
Term
(in thousands)
Outstanding at June 30, 2025
60,253
$
121.41
Granted
8,379
266.17
Exercised
( 15,612 )
109.36
Expired or forfeited
( 618 )
$
152.22
Outstanding at March 31, 2026
52,402
$
147.78
7.7 years
$
6,175
Exercisable at March 31, 2026
26,707
$
108.01
6.7 years
$
4,206
The following summarizes RSU award activity during the nine months ended March 31, 2026:
Weighted-
Average
Shares
Fair Value
Nonvested at June 30, 2025
355,396
$
116.34
Granted
228,513
226.56
Vested
( 338,715 )
162.21
Forfeited
( 2,316 )
120.49
Nonvested at March 31, 2026
242,878
$
156.03
22
Table of Contents
As of March 31, 2026, there were approximately 1.6 million shares available for grant under the OSI Plan. Under the terms of the OSI Plan, RSUs granted from the pool of shares available for grant reduce the pool by 1.87 shares for each award granted. RSUs forfeited and returned to the pool of shares available for grant increase the pool by 1.87 shares for each award forfeited.
We granted 80,682 and 49,431 performance-based RSUs during the nine months ended March 31, 2025 and 2026, respectively. These performance-based RSU awards are contingent on the achievement of certain performance metrics. The payout related to these awards can range from zero to 280 % of the original number of shares or units awarded. Compensation cost associated with these performance-based RSUs are recognized based on the estimated number of shares that we ultimately expect will vest. If the estimated number of shares to vest is revised in the future, then stock-based compensation expense will be adjusted accordingly.
Stock Repurchase Program
In September 2022, our Board of Directors increased the stock repurchase authorization to a total of 2 million shares. This program does not expire unless our Board of Directors acts to terminate the program. The timing and actual numbers of shares to be purchased under this program will depend on a variety of factors, including stock price, general business and market conditions and other investment opportunities. Repurchases may be made from time to time under the program through open-market purchases or privately-negotiated transactions at our discretion. Upon repurchase, the shares are restored to the status of authorized but unissued shares, and we record them in our consolidated financial statements as a reduction in the number of shares of common stock issued and outstanding, with the excess purchase price over par value recorded as a reduction of additional paid-in capital. If additional paid-in capital were to be reduced to zero, we would record the remainder of the excess purchase price over par value as a reduction of retained earnings.
During the nine months ended March 31, 2026, we repurchased 546,945 shares of common stock for an aggregate purchase price of $ 146.1 million in connection with the issuance of the 2031 Notes. As of March 31, 2026, there were 643,611 shares remaining available for repurchase under the authorized repurchase program.
Dividends
We have not paid any dividends since the consummation of our initial public offering in 1997 and we do not currently intend to pay any dividends in the foreseeable future. Our Board of Directors will determine the payment of future dividends, if any. Certain of our current bank credit facilities restrict the payment of dividends and future borrowings may contain similar restrictions.
10. Commitments and Contingencies
Acquisition-Related Contingent Obligations
Under the terms and conditions of the purchase agreements associated with certain acquisitions, we may be obligated to make additional payments based on the achievement of certain sales or profitability milestones through the acquired operations. For agreements that contain contingent consideration obligations, the remaining maximum amount of such potential future payments is $ 37.9 million as of March 31, 2026.
Projections and estimated probabilities are used to estimate future contingent earnout payments, which are discounted back to present value to compute contingent earnout liabilities. The following table provides a roll-forward from June 30, 2025 to March 31, 2026 of the contingent consideration liability, which is included in other accrued expenses and current liabilities and other long-term liabilities in our consolidated balance sheets (in thousands):
Beginning fair value, June 30, 2025
$
19,086
Foreign currency translation adjustment
( 71 )
Changes in fair value for contingent earnout obligations
( 7,235 )
Payments on contingent earnout obligations
( 486 )
Ending fair value, March 31, 2026
$
11,294
23
Table of Contents
Guarantees
We are periodically required to provide performance bonds to do business with certain customers. These arrangements are common in the industry and generally have terms ranging between one year and ten years . The bonds are provided by various bonding agencies. However, we are ultimately liable for claims that may occur against them. As of June 30, 2025 and March 31, 2026, we had a maximum financial exposure related to performance bonds of approximately $ 104 million and $ 100 million, respectively. As described in Note 8, we and several of our foreign subsidiaries have issued letters of credit under the revolving credit facility and international bank facilities. These letters of credit are issued to protect various customers, suppliers and government agencies under contractual arrangements and regulatory requirements. We have no history of significant claims and there are no pending matters that would require us to perform under any of these arrangements, and we believe that the resolution of any claims that might arise in the future, either individually or in the aggregate, would not materially affect the consolidated financial statements. Accordingly, no liability for any of these arrangements has been recorded as of June 30, 2025 and March 31, 2026.
Environmental Contingencies
We are subject to various environmental laws. We conduct environmental investigations at our manufacturing facilities in North America, Asia-Pacific, and Europe, and, to the extent practicable, on all new properties in order to identify, as of the date of such investigation, potential areas of environmental concern related to past and present activities or from nearby operations. In certain cases, we have conducted further environmental assessments consisting of soil and groundwater testing and other investigations deemed appropriate by independent environmental consultants.
We have not accrued for loss contingencies relating to environmental matters because we believe that, although unfavorable outcomes are possible, they are not considered by our management to be probable and reasonably estimable. If one or more of these environmental matters are resolved in a manner adverse to us, the impact on our business, financial condition, results of operations and cash flow could be material.
Indemnifications
In the normal course of business, we have agreed to indemnify certain parties with respect to certain matters. We have agreed to hold certain parties harmless against losses arising from a breach of representations, warranties or covenants, or intellectual property infringement or other claims made by third parties. These agreements may limit the time within which an indemnification claim can be made and the amount of the claim. In addition, we have entered into indemnification agreements with our directors and certain of our officers. It is not possible to determine the maximum potential amount under these indemnification agreements due to, among other factors, the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. We have not recorded any liability for costs related to contingent indemnification obligations as of March 31, 2026.
Product Warranties
We offer our customers warranties on many of the products that we sell. These warranties typically provide for repairs and maintenance of the products if problems arise during a specified time period after original shipment. Concurrent with the sale of products, we record a provision for estimated warranty expenses with a corresponding increase in cost of goods sold. We periodically adjust this provision based on historical experience and anticipated expenses. We charge actual expenses of repairs under warranty, including parts and labor, to this provision when incurred. The current obligation for warranty provision is included in other accrued expenses and current liabilities and the noncurrent portion is included in other long-term liabilities in the consolidated balance sheets.
The following table presents changes in warranty provisions (in thousands):
Nine Months Ended March 31,
2025
2026
Balance at beginning of period
$
11,089
$
11,612
Additions
4,171
2,369
Reductions for warranty repair costs and adjustments
( 3,630 )
( 4,376 )
Balance at end of period
$
11,630
$
9,605
24
Table of Contents
Legal Proceedings
We are involved in potential or actual claims, litigation and other legal proceedings arising in the ordinary course of business. In our opinion after consultation with legal counsel, the ultimate disposition of such proceedings is not likely to have a material adverse effect on our business, financial condition, results of operations or cash flows. We have not accrued for loss contingencies relating to any non-ordinary course matters because we believe that, although unfavorable outcomes in the proceedings are possible, they are not considered by management to be probable and reasonably estimable. If one or more of these matters are resolved in a manner adverse to our Company, the impact on our business, financial condition, results of operations and cash flows could be material.
11. Income Taxes
The determination of the annual effective tax rate is based upon a number of significant estimates and judgments, including the estimated annual pretax income in each tax jurisdiction in which we operate and the development of tax planning strategies during the year. In addition, as a global commercial enterprise, our tax expense can be impacted by changes in tax rates or laws, the finalization of tax audits and reviews and other factors that cannot be predicted with certainty. As such, there can be significant volatility in interim tax provisions.
The effective tax rates for the three months ended March 31, 2025 and 2026 were 14.3 % and 18.3 %, respectively. During the three months ended March 31, 2025, we recognized a net discrete tax benefit of $ 4.5 million related to equity-based compensation under ASU 2016-09 and changes in prior year tax estimates and uncertain tax positions. During the three months ended March 31, 2026 we recognized a net discrete tax benefit of $ 0.4 million related to equity-based compensation under ASU 2016-09 and a benefit of $ 2.3 million for changes in uncertain tax positions from prior years. The effective tax rates for the nine months ended March 31, 2025 and 2026 were 19.5 % and 19.1 %, respectively. During the nine months ended March 31, 2025, we recognized net discrete tax benefits of $ 1.3 million related to equity-based compensation under ASU 2016-09 and $ 4.0 million for changes in prior-years tax estimates and uncertain tax positions. During the nine months ended March 31, 2026, we recognized net discrete tax benefits of $ 2.1 million related to equity-based compensation under ASU 2016-09 and $ 3.3 million for changes in prior-years tax estimates and uncertain tax positions.
On July 4, 2025, the One Big Beautiful Bill Act (the “OBBBA”) was signed into law. Key income-tax related provisions of the OBBBA relevant to our Company include the removal of mandatory capitalization of domestic research and development expenditures, permanent extension of bonus depreciation and revisions to international tax regimes. We are evaluating the financial impact of OBBBA, which is in effect for the current fiscal year ending June 30, 2026. The legislation will affect the timing and recognition of certain deductions, which, if implemented, could impact our effective tax rate and deferred tax balances in future periods.
12. Segment Information
We operate in three identifiable industry segments: (a) security and inspection systems (Security division), (b) optoelectronic devices and manufacturing (Optoelectronics and Manufacturing division) and (c) medical monitoring systems (Healthcare division). We also have a corporate segment (Corporate) that includes executive compensation and certain other general and administrative expenses, expenses related to stock issuances and legal, audit and other professional service fees not allocated to industry segments. Both the Security and Healthcare divisions comprise primarily end-product businesses, whereas the Optoelectronics and Manufacturing division primarily supplies components and subsystems to external OEM customers, as well as to the Security and Healthcare divisions. Sales between divisions are at transfer prices that approximate market values. All other accounting policies of the segments are the same as described in Note 1, Basis of Presentation. We disclose segment income (loss) from operations as our measure of segment profit/loss, reconciled to consolidated income (loss) from operations. The measure of segment income (loss) from operations excludes impairment, restructuring and other charges presented below which are presented to reconcile to consolidated income from operations. Business segment disclosures consider information used by/provided to our chief operating decision maker (“CODM”). Our Chief Executive Officer serves as the CODM. The CODM uses segment income (loss) from operations, as well as the expenses within each segment including cost of sales, selling, general and administrative expenses and research and development expenses, to allocate resources to segments in the budgeting and forecasting process along with periodic ongoing reviews of results and overall activity in the markets where each segment operates.
25
Table of Contents
The following tables present our results of operations and identifiable assets by our three industry segments, along with amounts for Corporate/Eliminations, which are reconciled to consolidated amounts (in thousands):
Three Months Ended March 31, 2025
Optoelectronics
and
Security
Manufacturing
Healthcare
Corporate/
Division
Division
Division
Eliminations
Consolidated
Revenues (1):
External customer revenue
$
314,908
$
85,724
$
43,722
$
—
$
444,354
Revenue between segments
—
15,136
—
( 15,136 )
—
Total revenues
314,908
100,860
43,722
( 15,136 )
444,354
Cost of goods sold
209,498
77,926
21,663
( 15,024 )
294,063
Selling, general and administrative expenses
39,499
7,942
15,827
9,981
73,249
Research and development expenses
13,003
1,270
4,297
—
18,570
Segment income (loss) from operations
52,908
13,722
1,935
( 10,093 )
58,472
Impairment, restructuring and other charges
1,403
72
627
153
2,255
Income (loss) from operations
$
51,505
$
13,650
$
1,308
$
( 10,246 )
$
56,217
Capital expenditures
$
1,787
$
1,234
$
132
$
1,365
$
4,518
Depreciation and amortization
$
7,262
$
1,629
$
1,269
$
407
$
10,567
(1) For the three months ended March 31, 2025, one customer in the Security division accounted for 14 % of the Company’s consolidated net revenues.
Three Months Ended March 31, 2026
Optoelectronics
and
Security
Manufacturing
Healthcare
Corporate/
Division
Division
Division
Eliminations
Consolidated
Revenues (2):
External customer revenue
$
319,263
$
93,282
$
40,701
$
—
$
453,246
Revenue between segments
—
17,716
—
( 17,716 )
—
Total revenues
319,263
110,998
40,701
( 17,716 )
453,246
Cost of goods sold
213,141
87,219
20,167
( 17,605 )
302,922
Selling, general and administrative expenses
37,172
7,884
15,637
10,794
71,487
Research and development expenses
13,546
1,282
4,627
—
19,455
Segment income (loss) from operations
55,404
14,613
270
( 10,905 )
59,382
Impairment, restructuring and other charges
1,433
—
2,636
2,099
6,168
Income (loss) from operations
$
53,971
$
14,613
$
( 2,366 )
$
( 13,004 )
$
53,214
Capital expenditures
$
5,681
$
834
$
690
$
354
$
7,559
Depreciation and amortization
$
6,217
$
1,790
$
1,040
$
475
$
9,522
(2) For the three months ended March 31, 2026, no customer accounted for 10% or more of the Company’s consolidated net revenues.
26
Table of Contents
Nine Months Ended March 31, 2025
Optoelectronics
and
Security
Manufacturing
Healthcare
Corporate/
Division
Division
Division
Eliminations
Consolidated
Revenues (3):
External customer revenue
$
829,209
$
253,294
$
125,678
$
—
$
1,208,181
Revenue between segments
—
46,104
—
( 46,104 )
—
Total revenues
829,209
299,398
125,678
( 46,104 )
1,208,181
Cost of goods sold
536,651
233,921
63,801
( 45,136 )
789,237
Selling, general and administrative expenses
118,121
24,443
44,683
28,947
216,194
Research and development expenses
38,141
3,874
12,585
—
54,600
Segment income (loss) from operations
136,296
37,160
4,609
( 29,915 )
148,150
Impairment, restructuring and other charges
1,882
619
779
368
3,648
Income (loss) from operations
$
134,414
$
36,541
$
3,830
$
( 30,283 )
$
144,502
Capital expenditures
$
10,945
$
3,299
$
690
$
2,779
$
17,713
Depreciation and amortization
$
22,001
$
5,513
$
3,945
$
1,205
$
32,664
(3) For the nine months ended March 31, 2025, one customer in the Security division accounted for 13 % of the Company’s consolidated net revenues.
Nine Months Ended March 31, 2026
Optoelectronics
and
Security
Manufacturing
Healthcare
Corporate/
Division
Division
Division
Eliminations
Consolidated
Revenues (4):
External customer revenue
$
908,216
$
275,732
$
117,978
$
—
$
1,301,926
Revenue between segments
—
57,279
—
( 57,279 )
—
Total revenues
908,216
333,011
117,978
( 57,279 )
1,301,926
Cost of goods sold
612,645
262,087
58,048
( 55,992 )
876,788
Selling, general and administrative expenses
111,339
25,596
42,480
29,228
208,643
Research and development expenses
41,104
3,795
14,742
—
59,641
Segment income (loss) from operations
143,128
41,533
2,708
( 30,515 )
156,854
Impairment, restructuring and other charges
5,087
261
4,325
2,099
11,772
Income (loss) from operations
$
138,041
$
41,272
$
( 1,617 )
$
( 32,614 )
$
145,082
Capital expenditures
$
13,432
$
4,228
$
2,226
$
1,386
$
21,272
Depreciation and amortization
$
19,466
$
5,191
$
3,277
$
1,454
$
29,388
(4) For the nine months ended March 31, 2026, no customer accounted for 10% or more of the Company’s consolidated net revenues.
June 30,
March 31,
2025
2026
Assets (1) —by Segment:
Security division
$
1,608,985
$
1,676,393
Optoelectronics and Manufacturing division
300,405
298,898
Healthcare division
270,428
284,204
Corporate/Eliminations (2)
61,439
294,936
Total
$
2,241,257
$
2,554,431
(1) As of June 30, 2025 and March 31, 2026, one customer in the Security division accounted for 42 % and 40 % of the Company’s accounts receivable, net, respectively.
(2) Eliminations in assets reflect the amount of inter-segment profits in inventory and inter-segment ROU assets under ASC 842 as of the balance sheet date. Such inter-segment profit in inventory will be realized when the associated inventory is shipped to the external customers of the Security and Healthcare divisions.
27
Table of Contents
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.